Neville Rodie & Shaw Inc. lessened its holdings in Pfizer, Inc. (NYSE:PFE) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 196,481 shares of the biopharmaceutical company’s stock after selling 1,325 shares during the quarter. Neville Rodie & Shaw Inc.’s holdings in Pfizer were worth $6,600,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Fisher Asset Management LLC raised its position in Pfizer by 1.7% during the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock worth $1,120,704,000 after acquiring an additional 554,777 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Pfizer by 1.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after acquiring an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its position in Pfizer by 0.9% during the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Boston Partners raised its position in Pfizer by 7.3% during the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Pfizer by 1.0% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,376,931 shares of the biopharmaceutical company’s stock worth $594,465,000 after acquiring an additional 169,073 shares in the last quarter. 69.00% of the stock is currently owned by institutional investors and hedge funds.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock valued at $15,813,961 in the last ninety days. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Neville Rodie & Shaw Inc. Cuts Stake in Pfizer, Inc. (PFE)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/neville-rodie-shaw-inc-cuts-stake-in-pfizer-inc-pfe.html.

PFE has been the topic of several analyst reports. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $37.83.

Pfizer, Inc. (PFE) traded down 0.25% during trading on Tuesday, hitting $35.46. 5,553,473 shares of the company traded hands. The stock has a 50 day moving average price of $33.71 and a 200 day moving average price of $33.53. The company has a market capitalization of $210.89 billion, a P/E ratio of 25.94 and a beta of 1.00. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.84.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the firm posted $0.64 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s payout ratio is presently 94.12%.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.